Retrophin's Focus Shifts After Phase III PKAN Drug's Failure

 
• By Joseph Haas

Fosmetpantotenate missed all endpoints in a Phase III trial, so Retrophin will shelve the candidate for the rare disease PKAN. Now, the biotech turns focus to Phase III sparsentan in a pair of indications.

Child-Sorrow
Retrophin misses its Phase III endpoint in PKAN, which typically manifests in childhood

More from Clinical Trials

More from R&D